IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Staines, Henry M, Kirwan, Daniela E, Clark, David J, Adams, Emily ORCID: https://orcid.org/0000-0002-0816-2835, Augustin, Yolanda, Byrne, Rachel, Cocozza, Michael, CubasAtienzar, Ana, Cuevas, Luis ORCID: https://orcid.org/0000-0002-6581-0587, Cusinato, Martina, Davies, Benedict M O, Davis, Mark, Davis, Paul, Duvoix, Annelyse, Eckersley, Nicholas M, Forton, Daniel, Fraser, Alice, Garrod, Gala, Hadcocks, Linda, Hu, Qinxue, Johnson, Michael, Kay, Grant Alistair, Klekotko, Kesja, Lewis, Zawditu, Mensah-Kane, Josephine, Menzies, Stefanie ORCID: https://orcid.org/0000-0002-9273-9296, Monahan, Irene, Moore, Catherine, Nebe-von-Caron, Gerhard, Owen, Sophie ORCID: https://orcid.org/0000-0002-0458-2357, Sainter, Chris, Sall, Amadou A, Schouten, James, Williams, Chris, Wilkins, John, Woolston, Kevin, Fitchett, Joseph R A, Krishna, Sanjeev and Planche, Tim (2021) 'IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection'. Emerging Infectious Diseases, Vol 27, Issue 1, pp. 85-91.

Text Luis Cuevas SARS-CoV-2 Antibody Responses EID accepted (002).docx - Accepted Version Download (695kB)

Abstract

We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29–May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%–8.5% of persons did not seroconvert 3–6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection.

Item Type:	Article
Subjects:	QW Microbiology and Immunology > Antigens and Antibodies. Toxins and Antitoxins > QW 575 Antibodies WA Public Health > WA 105 Epidemiology WC Communicable Diseases > Virus Diseases > General Virus Diseases > WC 500 Virus diseases (General or not elsewhere classified) WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 505 Viral respiratory tract infections WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 518 Respirovirus Infections
Faculty: Department:	Biological Sciences > Department of Tropical Disease Biology Biological Sciences > Vector Biology Department
Digital Object Identifer (DOI):	https://doi.org/10.3201/eid2701.203074
Depositing User:	Rachael O'Donoghue
Date Deposited:	12 Jan 2021 11:41
Last Modified:	12 Jan 2021 11:42
URI:	https://archive.lstmed.ac.uk/id/eprint/16268

Statistics

View details

Actions (login required)

Edit Item